Xywav Narcolepsy Drug Scores FDA Approval for Rare Sleep Disorder

The US Food and Drug Administration (FDA) has approved a new indication for Jazz Pharmaceuticals’ (Nasdaq: JAZZ) Xywav for idiopathic hypersomnia (IH) in adults. IH is a rare chronic sleep disorder that causes people to be extra sleepy during the daytime despite getting eight or nine hours worth of a good night’s sleep.